RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 6 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with unresectable hepatocellular carcinoma (uHCC) who received donafenib, an anti-PD-1/L1 monoclonal antibody combined with transarterial interventional therapy (TACE or HAIC), with retrievable records in the hospital electronic information system between June 1, 2021 and November 30, 2024.

    Inclusion criterion 1

    No prior systemic therapy before the administration of donafenib, anti-PD-1/L1 monoclonal antibody combined with transarterial interventional therapy (TACE or HAIC).

    Inclusion criterion 4

    For patients who have previously undergone hepatectomy, the resection must be R0, and tumor recurrence must have occurred more than 24 months after surgery.

    Inclusion criterion 6

    History of malignancy other than hepatocellular carcinoma, unless meeting the following criteria: a) The patient received potentially curative treatment and there has been no evidence of disease for 5 years; b) Successfully treated resected cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, or other carcinoma in situ;

    Exclusion criterion 4

  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1.

    Inclusion criterion 8

  4. Hemoglobin ≥90 g/L;

    Inclusion criterion 11

    Absolute neutrophil count (ANC) ≥1.5×10⁹/L;

    Inclusion criterion 12

    Platelet count ≥75×10⁹/L;

    Inclusion criterion 13

    Total bilirubin ≤2× upper limit of normal (ULN);

    Inclusion criterion 16

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5× ULN;

    Inclusion criterion 17

    Alkaline phosphatase (ALP) ≤5× ULN;

    Inclusion criterion 18

    Creatinine ≤1.5× ULN;

    Inclusion criterion 19

    International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN;

    Inclusion criterion 21

    Activated partial thromboplastin time (APTT) ≤1.5× ULN.

    Inclusion criterion 22

  5. At least one evaluable lesion (according to RECIST v1.1 criteria).

    Inclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07724951, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with unresectable hepatocellular carcinoma (uHCC) who received donafenib, an anti-PD-1/L1 monoclonal antibody combined with transarterial interventional therapy (TACE or HAIC), with retrievable records in the hospital electronic information system between June 1, 2021 and November 30, 2024.
  • Diagnosis of hepatocellular carcinoma confirmed by the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) clinically or by histology/cytology.
  • Age ≥18 years, regardless of sex.
  • No prior systemic therapy before the administration of donafenib, anti-PD-1/L1 monoclonal antibody combined with transarterial interventional therapy (TACE or HAIC).
  • The maximum interval between the initiation of donafenib, anti-PD-1/L1 monoclonal antibody, and transarterial interventional therapy (TACE or HAIC) does not exceed 8 weeks, and at the time the last of these treatment modalities is initiated, the subject must not have experienced disease progression.
  • For patients who have previously undergone hepatectomy, the resection must be R0, and tumor recurrence must have occurred more than 24 months after surgery.
  • At least one evaluable lesion (according to RECIST v1.1 criteria).
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1.
  • Child-Pugh class A or B.
  • Adequate major organ function, defined by the following criteria:

Complete blood count (without blood transfusion or use of granulocyte colony-stimulating factor [G-CSF] within 14 days prior to screening):

  • Hemoglobin ≥90 g/L;
  • Absolute neutrophil count (ANC) ≥1.5×10⁹/L;
  • Platelet count ≥75×10⁹/L;
  • Blood biochemistry (without albumin use within 14 days prior to screening):
  • Albumin ≥28 g/L;
  • Total bilirubin ≤2× upper limit of normal (ULN);
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5× ULN;
  • Alkaline phosphatase (ALP) ≤5× ULN;
  • Creatinine ≤1.5× ULN;
  • Coagulation function:
  • International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN;
  • Activated partial thromboplastin time (APTT) ≤1.5× ULN.

Exclusion Criteria:

  • Incomplete or unavailable patient information data; patient refused follow-up or was lost to follow-up;
  • Duration of donafenib, PD-1/L1 monoclonal antibody combined with transarterial intervention therapy was less than 1 month;
  • Prior histologically/cytologically confirmed diagnosis of fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, or other components;
  • History of malignancy other than hepatocellular carcinoma, unless meeting the following criteria: a) The patient received potentially curative treatment and there has been no evidence of disease for 5 years; b) Successfully treated resected cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, or other carcinoma in situ;

Quoted from ClinicalTrials.gov, NCT07724951, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07724951, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07724951